NeuroMetrix (NURO) Sees Wild Action After FDA 510 (k) clearance
Tweet Send to a Friend
NeuroMetrix Inc. (Nasdaq: NURO) is off the highs, but still up 4 percent Monday, after FDA 510 (k) clearance for the company's Sensus nerve stimulator for pain relief. Link
Shares were as high as 29 percent earlier.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares were as high as 29 percent earlier.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Neurometrix (NURO) Files 3.98M Common Shelf for Shareholders
- Boston Scientific (BSX) Implements Vercise DBS in INTREPID Trial
- CryoLife (CRY) Conditionally Approved to Start PerClot Trials in U.S.
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
